Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor

• DOI: 10.1371/journal.pone.0114828
• Publication Date: 2015-01-28T18:57:33Z
• Authors: Shantashri Vaidya; Babu Rao Vundinti; Chandrakala Shanm...; Prantar Chakrabarti; Kanjaksha Ghosh
• Keywords: Philadelphia chromosome; ABL; Imatinib Mesylate; Protein kinase domain; breakpoint cluster region

Background Mutations in the ABL kinase domain and SH3-SH2 of BCR/ABL gene amplification Philadelphia chromosome are two important dependent mechanisms imatinib resistance. Here, we intended to study role played by TKI, imatinib, selection mutations development chromosomal abnormalities Indian CML patients. Methods Direct sequencing methodology was employed detect conventional cytogenetics done identify duplication. Results Among different resistance, (39%) were seen be more prevalent, followed (4%) then with least frequency (1%). The median duration occurrence mutation significantly shorter for patients front line than those pre-treated hydroxyurea. Patients high Sokal score (p = 0.003) showed higher incidence mutations, as compared low/intermediate score. Impact on clinical outcome AP BC observed insignificant. Of 94 resistant patients, only 1 patient exhibited duplication chromosome, suggesting a less frequent this abnormality Conclusion Close monitoring at regular intervals proper analysis disease resistance would facilitate early detection thus aid most appropriate therapy.